š£ VC round data is live. Check it out!
- Public Comps
- Vitrolife
Vitrolife Valuation Multiples
Discover Vitrolife's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Staar Surgical, Anbio Biotechnology, Nihon Kohden, Poly Medicure and more.
Vitrolife Overview
About Vitrolife
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patientās fertility treatment, thereby enabling patients to receiveĀ support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The group has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
Founded
1994
HQ

Employees
1.1K
Website
Financials (LTM)
EV
$1B
Valuation Multiples
Start free trialVitrolife Financials
Vitrolife reported last 12-month revenue of $382M and EBITDA of $114M.
In the same LTM period, Vitrolife generated $224M in gross profit, $114M in EBITDA, and had net loss of ($304M).
Revenue (LTM)
Vitrolife P&L
In the most recent fiscal year, Vitrolife reported revenue of $387M and EBITDA of $111M.
Vitrolife is unprofitable as of last fiscal year, with gross margin of 55%, EBITDA margin of 29%, and net margin of (139%).
Financial data powered by Morningstar, Inc.
Vitrolife Stock Performance
Vitrolife has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Vitrolife's stock price is $10.47.
Vitrolife share price decreased by 3.0% in the last 30 days, and by 30.7% in the last year.
Vitrolife has an EPS (earnings per share) of $-3.98.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | -2.2% | -3.0% | 1.6% | -30.7% | $-3.98 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVitrolife Valuation Multiples
Vitrolife trades at 3.9x EV/Revenue multiple, and 13.1x EV/EBITDA.
EV / Revenue (LTM)
Vitrolife Financial Valuation Multiples
As of June 4, 2026, Vitrolife has market cap of $1B and EV of $1B.
Vitrolife has a P/E ratio of (4.7x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Vitrolife Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Vitrolife Margins & Growth Rates
Vitrolife decreased revenue by 3% but EBITDA grew by 6% in the last fiscal year.
In the most recent fiscal year, Vitrolife reported gross margin of 55%, EBITDA margin of 29%, and net margin of (139%).
Vitrolife Margins
Vitrolife Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Vitrolife Operational KPIs
Vitrolife's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Vitrolife's Rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vitrolife's Rule of X is 35% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Vitrolife Competitors
Vitrolife competitors include Staar Surgical, Anbio Biotechnology, Nihon Kohden, Poly Medicure, Nolato, SKAN Group, Haier Biomedical, Savaria, El.En. Group and VCANBIO.
Most Vitrolife public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.9x | 4.6x | 23.7x | 67.3x | |||
| 162.7x | - | 244.0x | - | |||
| 0.9x | 0.9x | 7.8x | 8.1x | |||
| 6.8x | 6.6x | 22.9x | 27.5x | |||
| 1.4x | 1.4x | 8.5x | 8.5x | |||
| 3.5x | 3.3x | 30.5x | 25.9x | |||
| 3.6x | 3.5x | 21.3x | 21.2x | |||
| 2.4x | 2.3x | 11.6x | 11.2x | |||
This data is available for Pro users. Sign up to see all Vitrolife competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Vitrolife
Vitrolife has acquired 5 companies to date.
Last acquisition by Vitrolife was on May 2nd 2024. Vitrolife acquired eFertility for $10M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Vitrolife
| Description | - | Igenomix is a global leader in reproductive genetics headquartered in Valencia, Spain, with labs in 40 countries. It offers preimplantational genetic testing for aneuploidies, monogenic disorders, and mosaicism, alongside ERA endometrial receptivity analysis and miRNA endometrial assessment tests. The company supports IVF clinics with non-invasive prenatal testing and sperm DNA fragmentation analysis. | OCTAX Microscience GmbH is a Bruckberg-based manufacturer of specialized medical devices for in vitro fertilization procedures. The company produces micromanipulation systems, including inverted microscopes, laser systems for embryo biopsy, and imaging software tailored for reproductive clinics. OCTAX equipment supports intracytoplasmic sperm injection, polar body biopsy, and trophectoderm biopsy workflows. With a focus on precision optics and automation, the firm serves fertility centers across Europe and beyond from its German headquarters. | MTG-Medical Technology Vertriebs is a Bruckberg-headquartered supplier of equipment and consumables for assisted reproductive technology laboratories worldwide. Delivers specialized products such as RI Witness tracking systems, MIRI time-lapse incubators, and micromanipulation workstations essential for IVF procedures. Collaborates with scientific partners on advancements in gamete preparation and embryo monitoring technologies. Provides end-to-end services including application training, technical support, and preventive maintenance through direct staff and regional partners. Established in 1999, supports fertility clinics primarily across Europe with tailored solutions for workflow optimization. | |
| HQ Country | |||||
| HQ City | - | Valencia | Bruckberg | Bruckberg | |
| Deal Date | 2 May 2024 | 8 Jul 2021 | 1 Jun 2016 | 1 Jun 2016 | |
| Valuation | $10M | $1B | $15M | $15M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Vitrolife acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Vitrolife
| When was Vitrolife founded? | Vitrolife was founded in 1994. |
| Where is Vitrolife headquartered? | Vitrolife is headquartered in Sweden. |
| How many employees does Vitrolife have? | As of today, Vitrolife has over 1K employees. |
| Who is the CEO of Vitrolife? | Vitrolife's CEO is Bronwyn Brophy. |
| Is Vitrolife publicly listed? | Yes, Vitrolife is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Vitrolife? | Vitrolife trades under VITR ticker. |
| When did Vitrolife go public? | Vitrolife went public in 2001. |
| Who are competitors of Vitrolife? | Vitrolife main competitors include Staar Surgical, Anbio Biotechnology, Nihon Kohden, Poly Medicure, Nolato, SKAN Group, Haier Biomedical, Savaria, El.En. Group, VCANBIO. |
| What is the current market cap of Vitrolife? | Vitrolife's current market cap is $1B. |
| What is the current revenue of Vitrolife? | Vitrolife's last 12 months revenue is $382M. |
| What is the current revenue growth of Vitrolife? | Vitrolife revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Vitrolife? | Current revenue multiple of Vitrolife is 3.9x. |
| What is the current EBITDA of Vitrolife? | Vitrolife's last 12 months EBITDA is $114M. |
| What is Vitrolife's EBITDA margin? | Vitrolife's last 12 months EBITDA margin is 30%. |
| What is the current EV/EBITDA multiple of Vitrolife? | Current EBITDA multiple of Vitrolife is 13.1x. |
| What is the current FCF of Vitrolife? | Vitrolife's last 12 months FCF is $52M. |
| What is Vitrolife's FCF margin? | Vitrolife's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Vitrolife? | Current FCF multiple of Vitrolife is 28.5x. |
| How many companies Vitrolife has acquired to date? | As of June 2026, Vitrolife has acquired 5 companies. |
| What was the largest acquisition by Vitrolife? | $1B acquisition of Igenomix on 8th July 2021 was the largest M&A Vitrolife has done to date. |
| In how many companies Vitrolife has invested to date? | Vitrolife hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Vitrolife
Lists including Vitrolife
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.


